Project Name: Pharmacist-Led Lipid Management Model of Care at PCN Level

Project Summary:

The key aim of the Collaborative Working Project is to improve lipid management at speed and scale at the PCN level and improve the quality of care for patients with with Atherosclerotic Cardiovascular Disease (ASCVD) and uncontrolled lipid levels.

The project in Wallsend PCN aims to address critical limitations within the system to the identification and treatment of ASCVD patients to ensure that appropriately treated patients benefit from all available therapies without unnecessary delay.  

The service will aim to achieve:

1. Identification of sub-optimally treated patients who are not achieving lipid levels as specified by local guidelines
2. Identification of patients who have previously not tolerated or refused alternative lipid modification therapies
3. Review treatment options in a consultative way with patients
4. Counsel and optimise patients where appropriate

Planned Milestones:

  • PCN Level Lipid Management pathway/protocol development 
  • Collection of baseline data, in line with the measure of success 
  • Collection of 3 months clinical activity data & Project Review meeting to discuss project progress. 
  • Collection of 6 months clinical activity data & Project Review meeting to discuss project progress. 
  • Collection of 9 months clinical activity data & Project Review meeting to discuss project progress. 
  • Collection of 12 months clinical activity data & Project Review meeting to discuss project progress. 
  • Collection of 15 months clinical activity data & Project Review meeting to discuss project progress. 
  • Collection of 18 months clinical activity data & Project Review meeting to discuss project progress. 
  • Analysis of project data, and Submission of Outcomes Summary  
  • Development of Final Project Write-up by 3rd Party

Expected Benefits:

Anticipated benefits for patients:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
  • Enhanced experience and counselling around ASCVD with ongoing management of the condition.
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up.
  • Reduced risk of ASCVD event leading to reduced risk of patient mortality and morbidity.

Anticipated benefits for partner organisation:

  • Increased proportion of ASCVD patients reviewed by primary care
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home
  • Reduction in ASCVD referral rates to secondary care
  • Increased proportion of patients receiving guideline-directed pharmacotherapy
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care
  • Opportunity to show the impact of the CWP to create lasting change in lipid management within the PCN

Anticipated benefits for Novartis:

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine 
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with the NHS which addresses the problem of health inequalities 
  • Ethical, professional, and transparent relationship between Novartis and the NHS 

Start Date & Duration: August 2022 – 22 months

UK2208261741